ROCKVILLE, MD, December 30, 2022 (GLOBE NEWSWIRE) – OncoC4 announced today the initiation of dosing in the first patient for a Phase 2 clinical trial evaluating the combination of ONC-392, a next-generation anti-CTLA-4 antibody, and KEYTRUDA (pembrolizumab), an anti-PD-1 antibody from Merck & Co., Inc., in patients with platinum-resistant ovarian cancer (PROC). The trial, named PRESERVE-004 (NCT05446298), has successfully administered its first dose to a patient.
The first patient received their initial treatment at the Women’s Cancer Hospital in Albany, New York. Dr. Joyce Barlin is the principal investigator (PI) at this center. This Phase 2 clinical trial is sponsored by OncoC4 and is being conducted in collaboration with Merck & Co., Inc. (known as Merck in the U.S. and Canada) and the Gynecologic Oncology Group (GOG) Foundation.
